Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Release Date

August 29, 2024

Expiration Date

December 1, 2025

Credits

1.0 CME, NCPD

Release Date: August 29, 2024

Expiration Date: November 30, 2025

Activity Overview

This SimulatEd™ program is an online, on-demand activity designed to enhance clinical reasoning for healthcare providers involved in the treatment of Alzheimer disease. It consists of simulated patient encounters. As the cases evolve, learners will be prompted to make clinical decisions and review updates on new data and best practices from expert faculty, fostering critical thinking and decision-making skills in a risk-free setting. The focus of these activities is on 2 individuals being evaluated for potential treatment of Alzheimer disease and guiding them through the role of genetic testing in their treatment journey.

Target Audience

This educational activity is directed toward geriatricians, neurologists, geriatric psychiatrists, dementia specialists, nurses, nurse practitioners, physician assistants, and other healthcare providers who may aid in the management of Alzheimer disease.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify the role of genetic testing in the evaluation of patients with suspected Alzheimer disease
  • Outline the role of genetic testing in patient selection for therapy for Alzheimer disease
  • Integrate genetic testing into management plans for patients with Alzheimer disease
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Eli Lilly and Company.

Course

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Create Account